β--DL-β-alanin-methylester | 140373-38-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: β--DL-β-alanin-methylester
• 英文别名: Methyl 3-amino-3-(3-nitrophenyl)propionate；Methyl 3-amino-3-(3-nitrophenyl)propanoate
• CAS: 140373-38-2
• 化学式: C₁₀H₁₂N₂O₄
• 分子量: 224.216
• InChiKey: WCYSVIMUYDWOPM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  98.1
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  β--DL-β-alanin-methylester 在 水 、 1-羟基苯并三唑 、 N,N'-二环己基碳二亚胺 、 sodium hydroxide 作用下， 以 四氯化碳 、 丙酮 为溶剂， 生成 3-benzamido-3-(3-nitrophenyl)propanoic acid
  参考文献：
  名称：

  Synthesis, in Vitro and in Vivo Biological Evaluation, and Comprehensive Understanding of Structure−Activity Relationships of Dipeptidyl Boronic Acid Proteasome Inhibitors Constructed from β-Amino Acids

  摘要：

  An extensive structure-activity relationship (SAR) study of 72 dipeptidyl boronic acid proteasome inhibitors constructed from beta-amino acids is reported. SAR analysis revealed that bicyclic groups at the RI position, 3-F substituents at the R-2 position, and bulky aliphatic groups at the R-3 position were favorable to the activities. Enzymatic screening results showed that compound 78, comprising all of these features, was the most active inhibitor against the 20S human proteasome at less than a 2 nM level, as active as the marketed drug bortezomib. Cellular assays confirmed that compound 78 was the most potent against two hematologic and some solid tumor cells with IC50 values less than 1 mu M. Pharmacokinetic profiles suggested that 78 showed higher plasma exposure and a longer half-life than bortezomib.

  DOI：

  10.1021/jm1009742
• 作为产物：
  描述：

  3-Amino-3-(3-nitrophenyl)propionamide 以 甲醇 为溶剂， 生成 β--DL-β-alanin-methylester
  参考文献：
  名称：

  Benzodiazepine cholecystokinin antagonists

  摘要：

  公开了一种公式为##STR1##的苯二氮平类似物，它们是胃泌素和胆囊收缩素(CCK)的拮抗剂。

  公开号：

  US05378838A1

文献信息

• Anti-tumor compounds
  申请人：Imperial Chemical Industries PLC

  公开号：US05280027A1

  公开（公告）日：1994-01-18

  The invention relates to quinazoline derivatives, or pharmaceutically-acceptable salts thereof, which possess anti-tumour activity; to processes for their manufacture; and to pharmaceutical compositions containing them. The invention provides a quinazoline of the formula: ##STR1## wherein R.sup.1 includes hydrogen, amino and alkyl or alkoxy each of up to 4 carbon atoms; R.sup.2 includes hydrogen, alkyl, hydroxyalkyl and halogenoalkyl each of up to 4 carbon atoms; R.sup.3 is hydrogen or alkyl or up to 3 carbon atoms; Ar is phenylene or heterocyclene; L is a group of the formula --CO.NH--, --NH.CO--, --CO.NR.sup.4 --, --NR.sup.4.CO--, --CH.dbd.CH-- or --CO.O--, wherein R.sup.4 is alkyl of up to 4 carbon atoms; and Y is a branched alkyl group bearing substituents Y.sup.2 and Y.sup.3 the definition of each independently including hydroxy, cyano, aryl and heteroaryl, and the definition of Y.sup.3 also optionally including sulpho, N-phenylsulphonylcarbamoyl and 5-tetrazolyl; or a pharmaceutically-acceptable salt thereof.

  本发明涉及喹唑啉衍生物，或其药用可接受的盐，这些衍生物具有抗肿瘤活性；提供它们的制造过程；以及含有它们的药物组合物。本发明提供了一种喹唑啉的公式：##STR1##其中，R.sup.1 包括氢、氨基和每个碳原子最多4个的烷基或烷氧基；R.sup.2 包括氢、烷基、羟烷基和卤代烷基，每个碳原子最多4个；R.sup.3 是氢或最多3个碳原子的烷基；Ar是苯基或杂环基；L是以下公式之一的基团：--CO.NH--，--NH.CO--，--CO.NR.sup.4 --，--NR.sup.4.CO--，--CH.dbd.CH--或--CO.O--，其中R.sup.4是碳原子最多4个的烷基；Y是带有取代基Y.sup.2和Y.sup.3的支链烷基，每个定义独立包括羟基、氰基、芳基和杂芳基，Y.sup.3的定义还可选包括磺酸基、N-苯磺酰氨基甲酰基和5-四唑基；或其药用可接受的盐。
• [EN] NOVEL AMINO AZAHETEROCYCLIC CARBOXAMIDES<br/>[FR] NOUVEAUX CARBOXAMIDES AMINO-AZAHÉTÉROCYCLIQUES
  申请人：MERCK PATENT GMBH

  公开号：WO2010093419A1

  公开（公告）日：2010-08-19

  The invention provides novel substituted amino azaheterocyclic carboxamide compounds according to Formula (I), their manufacture and use for the treatment of hyperproliferative diseases, such as cancer.

  该发明提供了根据式（I）提供的新型取代氨基氮杂杂环羧酰胺化合物，其制备和用于治疗高增殖性疾病，如癌症。
• &bgr;-alanine derivatives
  申请人：Merck Patent GmbH

  公开号：US06576637B1

  公开（公告）日：2003-06-10

  The invention relates to &bgr;-alanine derivatives of formula (I), wherein Q1, Q2, Q3, Q4, R1, R2, R3, R4, R5, R6 and n have the meaning as disclosed in the disclosure, and to their physiologically acceptable salts or solvates. Said substances are integrin inhibitors and can be used in the treatment of thrombosis, heart infarct, coronary heart diseases, arteriosclerosis, inflammations, tumors, osteoporosis, infections and restenosis after angioplasty or in pathological processes induced or propagated by angiogenesis.

  本发明涉及公式(I)中的β-丙氨酸衍生物，其中Q1、Q2、Q3、Q4、R1、R2、R3、R4、R5、R6和n的含义如披露所述，以及其生理上可接受的盐或溶剂。所述物质是整合素抑制剂，可用于治疗血栓、心肌梗塞、冠心病、动脉硬化、炎症、肿瘤、骨质疏松、感染以及在血管生成诱导或传播的病理过程中的再狭窄。
• Tan-1057 derivatives
  申请人：Bayer Aktiengesellschaft

  公开号：US06617332B1

  公开（公告）日：2003-09-09

  The invention relates to novel natural product derivatives of the formula (I), to processes for their preparation, to pharmaceutical compositions comprising them and to their use in the treatment of disorders in humans or animals: in which R1, D, X, Y and Z are defined as in claim 1.

  本发明涉及公式（I）的新型天然产物衍生物，其制备过程，包括它们的制药组合物以及它们在治疗人类或动物疾病中的应用：其中R1，D，X，Y和Z如权利要求1所定义。
• Novel Amino Azaheterocyclic Carboxamides
  申请人：Sutton Amanda E.

  公开号：US20120046269A1

  公开（公告）日：2012-02-23

  The invention provides novel substituted amino azaheterocyclic carboxamide compounds according to Formula (I), their manufacture and use for the treatment of hyperproliferative diseases, such as cancer.

  该发明提供了根据式(I)的新型取代氨基杂环羧酰胺化合物，其制备和用于治疗增生性疾病，如癌症。